JP Morgan calls the drug a potential “blockbuster”. Upgrades $RXRX to Overweight and slaps an $1... | Beanie

JP Morgan calls the drug a potential “blockbuster”. Upgrades $RXRX to Overweight and slaps an $1...

Twitter

Note: AI-generated summary based on third-party content. Not financial advice. Read more.

Quick Insights

JPMorgan has upgraded Recursion Pharmaceuticals ($RXRX) to Overweight with an $11 price target, citing "blockbuster potential" for its drug REC-4881 and strong efficacy for REC-617. This upgrade, coupled with the company's AI optionality in drug discovery, suggests a potential 3x return.

Ask about this postAnswers are grounded in this post's content.

About Beanie

Beanie

By beaniemaxi

Crypto native since the early days. Went all in on DeFi summer. Then tripled down on NFTs. VC @gmcapital_. No paid promos. Not financial advice. I talk my book.